HMN 2025: What is the Guidance issued for GPs managing weight-loss injection sufferers

Academics at King’s College London and the University of East Anglia have launched steerage for GPs on the way to handle sufferers who could also be privately accessing weight reduction medication.

The drugs aren’t routinely prescribed for weight problems administration in major care. But it’s estimated 1.5million people used weight-loss jabs in March 2025, with 80% of purchases by means of on-line retailers. As these customers are privately accessing the medicine, suppliers don’t all the time present wrap-around care resembling dietary recommendation or psychological help.

The authors of the steerage, published in Obesity Facts, say the ten evidence-based ideas intention to assist GPs who see sufferers utilizing these drugs in major care. Patients could not disclose using the jabs however could have a myriad of signs or indicators of use.

Lead writer Dr. Laurence Dobbie, Academic Clinical Fellow in General Practice, from King’s College London, mentioned, “More than 1,000,000 individuals are taking these medicines privately and seeing GPs with a number of completely different issues. We need GPs to have the essential information to prioritize affected person security and demystify unwanted side effects. I’ve seen sufferers in major care who’re clearly taking the drugs, however they have not been given wrap-around care.”

Key suggestions embrace:

• Ask about use: Adopt a non-judgemental method to uncover undisclosed weight reduction injection use when sufferers current with dizziness, falls, gastrointestinal signs or speedy weight change.
• Review medicines early: Consider the necessity to downtitrate insulin, sulphonylureas and antihypertensives to keep away from hypoglycaemia and postural hypotension as weight reduces.
• Watch for pink flags: Severe stomach ache could sign acute pancreatitis or biliary illness; pressing evaluation is suggested.
• Consider fertility and surgical procedure: Advise girls of child-bearing age to cease GLP-1 medication two months earlier than conception makes an attempt, and cease weekly drugs one week earlier than surgical procedure to decrease the possibility of liquid/meals coming into the lungs.

The steerage is the primary output of Obesity Management Collaborative UK, a community arrange in 2024 to help clinicians managing sufferers with weight problems. The community is chaired by Professor Barbara McGowan at King’s.

Professor Barbara McGowan from King’s College London and a Consultant Endocrinologist at Guy’s and St Thomas’ NHS Foundation Trust:

“OMC-UK was developed to offer training, skilled improvement and help to well being care professionals working in weight administration companies. These ten high ideas intention to upskill GPs within the administration and monitoring of sufferers on these drugs. By embedding these suggestions into routine medical practice, we will guarantee affected person security and optimize the care of people dwelling with weight problems.”

Dr. Helen Parretti, joint first writer and Consultant Clinical Associate Professor in Primary Care on the University of East Anglia, mentioned, “We hope that these ten high ideas will assist help GPs, and different well being care professionals working in major care, when managing sufferers on these drugs. They provide sensible, evidence-based steerage that has been designed to be simply accessible to busy well being care professionals.”

The article was developed by means of collaboration between consultants in major care (Dr. Laurence Dobbie, Dr. Helen Parretti, Dr. Ellen Fallows, Dr. Stephanie De Giorgio), endocrinologists (Prof Barbara McGowan, Dr. Dipesh Patel) and consultants by means of lived {experience} (Sarah Le Brocq).